Nova Mentis Life Science Corp.

CNSX:NOVA Stock Report

Market Cap: CA$2.2m

Nova Mentis Life Science Past Earnings Performance

Past criteria checks 0/6

Nova Mentis Life Science has been growing earnings at an average annual rate of 7.1%, while the Biotechs industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 0.09% per year.

Key information

7.1%

Earnings growth rate

23.9%

EPS growth rate

Biotechs Industry Growth51.1%
Revenue growth rate0.09%
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

This Is Why Nova Mentis Life Science Corp.'s (CSE:NOVA) CEO Compensation Looks Appropriate

Dec 09
This Is Why Nova Mentis Life Science Corp.'s (CSE:NOVA) CEO Compensation Looks Appropriate

We Think Nova Mentis Life Science (CSE:NOVA) Can Afford To Drive Business Growth

Dec 07
We Think Nova Mentis Life Science (CSE:NOVA) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown
Beta

How Nova Mentis Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:NOVA Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-110
30 Sep 230-210
30 Jun 230-210
31 Mar 230-220
31 Dec 220-220
30 Sep 220-220
30 Jun 220-321
31 Mar 220-321
31 Dec 210-321
30 Sep 210-2121
30 Jun 210-2020
31 Mar 210-2620
31 Dec 200-2520
30 Sep 200-710
30 Jun 200-710
31 Mar 200-110
31 Dec 190-110
30 Sep 190-210
30 Jun 190-220
31 Mar 190-220
31 Dec 180-430
30 Sep 180-430
30 Jun 180-430
31 Mar 180-430
31 Dec 170-210
30 Sep 170-320
30 Jun 170-220
31 Mar 170-210
31 Dec 160-210
30 Sep 160-110
30 Jun 160-110
31 Mar 160-110
31 Dec 150-110
30 Sep 150-210
30 Jun 150-210
31 Mar 150-210
31 Dec 140-200
30 Sep 140000
30 Jun 140000
31 Mar 140000
31 Dec 130000
30 Sep 130-600

Quality Earnings: NOVA is currently unprofitable.

Growing Profit Margin: NOVA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NOVA is unprofitable, but has reduced losses over the past 5 years at a rate of 7.1% per year.

Accelerating Growth: Unable to compare NOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NOVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).


Return on Equity

High ROE: NOVA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.